Literature DB >> 20362620

Vaccination strategies for managing brucellosis in Yellowstone bison.

John J Treanor1, Joseph S Johnson, Rick L Wallen, Sara Cilles, Philip H Crowley, John J Cox, David S Maehr, P J White, Glenn E Plumb.   

Abstract

Concerns over migratory bison (Bison bison) at Yellowstone National Park transmitting brucellosis (Brucella abortus) to cattle herds on adjacent lands led to proposals for bison vaccination. We developed an individual-based model to evaluate how brucellosis infection might respond under alternate vaccination strategies, including: (1) vaccination of female calves and yearlings captured at the park boundary when bison move outside the primary conservation area; (2) combining boundary vaccination with the remote delivery of vaccine to female calves and yearlings distributed throughout the park; and (3) vaccinating all female bison (including adults) during boundary capture and throughout the park using remote delivery of vaccine. Simulations suggested Alternative 3 would be most effective, with brucellosis seroprevalence decreasing by 66% (from 0.47 to 0.16) over a 30-year period resulting from 29% of the population receiving protection through vaccination. Under this alternative, bison would receive multiple vaccinations that extend the duration of vaccine protection and defend against recurring infection in latently infected animals. The initial decrease in population seroprevalence will likely be slow due to high initial seroprevalence (40-60%), long-lived antibodies, and the culling of some vaccinated bison that were subsequently exposed to field strain Brucella and reacted positively on serologic tests. Vaccination is unlikely to eradicate B. abortus from Yellowstone bison, but could be an effective tool for reducing the level of infection. Our approach and findings have applicability world-wide for managers dealing with intractable wildlife diseases that cross wildlife-livestock and wildlife-human interfaces and affect public health or economic well-being. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20362620     DOI: 10.1016/j.vaccine.2010.03.055

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge.

Authors:  Xinghong Yang; Beata Clapp; Theresa Thornburg; Carol Hoffman; David W Pascual
Journal:  Vaccine       Date:  2016-09-14       Impact factor: 3.641

2.  Efficacy of dart or booster vaccination with strain RB51 in protecting bison against experimental Brucella abortus challenge.

Authors:  S C Olsen; C S Johnson
Journal:  Clin Vaccine Immunol       Date:  2012-04-11

3.  Serological, molecular detection and potential risk factors associated with camel brucellosis in Pakistan.

Authors:  Sana Fatima; Iahtasham Khan; Amar Nasir; Muhammad Younus; Muhammad Saqib; Falk Melzer; Heinrich Neubauer; Hosny El-Adawy
Journal:  Trop Anim Health Prod       Date:  2016-09-27       Impact factor: 1.559

4.  Progress in Brucella vaccine development.

Authors:  Xinghong Yang; Jerod A Skyberg; Ling Cao; Beata Clapp; Theresa Thornburg; David W Pascual
Journal:  Front Biol (Beijing)       Date:  2013-02-01

Review 5.  Current Status of Rift Valley Fever Vaccine Development.

Authors:  Bonto Faburay; Angelle Desiree LaBeaud; D Scott McVey; William C Wilson; Juergen A Richt
Journal:  Vaccines (Basel)       Date:  2017-09-19

6.  Vaccination and monitoring strategies for epidemic prevention and detection in the Channel Island fox (Urocyon littoralis).

Authors:  Jessica N Sanchez; Brian R Hudgens
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

7.  Individual-based modelling and control of bovine brucellosis.

Authors:  Erivelton G Nepomuceno; Alípio M Barbosa; Marcos X Silva; Matjaž Perc
Journal:  R Soc Open Sci       Date:  2018-05-02       Impact factor: 2.963

Review 8.  Vaccines against diseases transmitted from animals to humans: a one health paradigm.

Authors:  Thomas P Monath
Journal:  Vaccine       Date:  2013-09-21       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.